

MOMENTUM BIOSCIENCE LIMITED

Registered Number
05594335
(England and Wales)

Unaudited Financial Statements for the Year ended
31 October 2022

MOMENTUM BIOSCIENCE LIMITED

Company Information for the year from 1 November 2021 to 31 October 2022

Directors

FROHN, Matthew Gerard Winston

MALHOTRA, Rajat

MANENT RELATS, Jose

MOFFITT, William Penn

MULLEN, William Henry, Dr

THAKER, Saumil

THURLOW, James William

Registered Address

Unit 19 Willowbrook Technology Park

Llandogo Road, St. Mellons

Cardiff

CF3 0EF

Registered Number

05594335 (England and Wales)

MOMENTUM BIOSCIENCE LIMITED

Balance Sheet as at 31 October 2022

	Notes	2022	2021
		£	£
Fixed assets			
Intangible assets	7	4,258,048	4,139,050
Tangible assets	8	162,983	95,796
		<u>4,421,031</u>	<u>4,234,846</u>
Current assets			
Debtors	9	761,891	417,986
Cash at bank and on hand		707,069	3,568,341
		<u>1,468,960</u>	<u>3,986,327</u>
Creditors amounts falling due within one year	10	(435,987)	(325,879)
		<u>1,032,973</u>	<u>3,660,448</u>
Net current assets (liabilities)		<u>5,454,004</u>	<u>7,895,294</u>
Total assets less current liabilities		<u>5,454,004</u>	<u>7,895,294</u>
Creditors amounts falling due after one year	11	(3,559,806)	(3,636,422)
		<u>()</u>	<u>()</u>
Net assets		<u>1,894,198</u>	<u>4,258,872</u>
Capital and reserves			
Called up share capital		21,223	20,532
Share premium		17,621,278	17,449,084
Profit and loss account		(15,748,303)	(13,210,744)
		<u>()</u>	<u>()</u>
Shareholders' funds		<u>1,894,198</u>	<u>4,258,872</u>

The company was entitled to exemption from audit for this reporting period under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The Directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime. The directors have chosen to not file a copy of the company's profit and loss

account.

The financial statements were approved and authorised for issue by the Board of Directors on 1 November 2022, and are signed on its behalf by:

THAKER, Saumil

Director

Registered Company No. 05594335

MOMENTUM BIOSCIENCE LIMITED

Notes to the Financial Statements for the year ended 31 October 2022

1. Statutory information

The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. Compliance with applicable reporting framework

The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.

3. Principal activities

The company's principal activity during the year continued to be focused on the development of high value diagnostic tests for blood stream infections in patients suspected of sepsis. Investment has been focused on SepsisSTAT, a rapid molecular detection and identification product that can be run directly from a patient's blood sample without the need for culturing. Capabilities developed in the process of optimising SepsisSTAT have led to patent filings and the initiation of clinical trials to evaluate performance.

During this time the management of Momentum remains committed to identifying, and collaborating with, potential strategic partners to further the commercial attractiveness of its products.

4. Accounting policies

Property, plant and equipment policy

Tangible fixed assets are stated at cost or valuation less depreciation. Depreciation is provided on all tangible fixed assets as follows:

Intangible assets policy

Intangible fixed assets are measured at cost less any accumulative impairment losses. Amortisation is not yet charged on intangible assets as the related benefits have not yet begun to flow.

Revenue recognition policy

Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.

Foreign currency translation and operations policy

Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.

Employee benefits policy

Contributions to defined contribution plans are expensed in the period to which they relate.

Going concern

The company is in the research and development phase of its technology and has incurred losses since it commenced activities in 2008. During the year to 31 October 2022 the company incurred a loss before taxation of £3,172,914 but had secured additional equity financing during the year, and at 31 October 2022 the company had net current assets of £1,894,198.

The accounts have been prepared on the "going concern" basis which assumes that the company will be able to continue to meet its financial obligations for a period of at least twelve months from the date of this report. In deciding that this basis was appropriate the Board considered its cashflow forecasts along with the appetite of the shareholder base for continued funding of the business and the likelihood of securing new investment if and as required.

5. Prior period and policy change adjustments

The balance sheet at October 2020 has been restated to include the acquired intangible asset and related creditor.

Payments to that creditor have been reallocated from expense to a reduction in the liability. The creditor balance has not been discounted for quasi financing costs as these are not considered material.

Amortisation has not been charged to the asset as the benefits accruing to ownership have not yet begun to flow. The directors have conducted an impairment review of the acquired patents and are comfortable with the carrying value.

Whilst carrying out these adjustments, amortisation previously charged to patent creation costs has been reversed as, again, the benefits accruing to ownership have not yet flowed. The directors have also conducted an impairment review of the portfolio.

6. Employee information

	2022	2021
Average number of employees during the year	18	12

7. Intangible assets

Intangible Fixed Assets has been restated to include intellectual property purchased in 2017 but that was not capitalised. The carrying value is £3,860,810.

Intangible Fixed Assets include patent costs & purchased patents but not internal research costs.

These are not yet amortised as the revenue which is expected to flow from these assets is expected in the future.

The directors conduct annual impairment reviews of the intellectual property portfolio.

	Other	Total
	£	£
Cost or valuation		
At 01 November 21	4,139,050	4,139,050
Additions	118,998	118,998
At 31 October 22	4,258,048	4,258,048
Net book value		
At 31 October 22	4,258,048	4,258,048
At 31 October 21	4,139,050	4,139,050

8. Property, plant and equipment

	Plant & machinery	Total
	£	£
Cost or valuation		
At 01 November 21	653,276	653,276
Additions	187,734	187,734
At 31 October 22	841,010	841,010
Depreciation and impairment		
At 01 November 21	557,480	557,480
Charge for year	120,547	120,547
At 31 October 22	678,027	678,027
Net book value		
At 31 October 22	162,983	162,983
At 31 October 21	95,796	95,796

9. Debtors

	2022	2021
	£	£
Other debtors	737,351	399,137
Prepayments and accrued income	24,540	18,849
Total	<u>761,891</u>	<u>417,986</u>

Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.

10. Creditors within one year

	2022	2021
	£	£
Trade creditors / trade payables	158,202	174,476
Bank borrowings and overdrafts	7,930	-
Taxation and social security	78,409	19,156
Other creditors	64,582	54,784
Accrued liabilities and deferred income	126,864	77,463
Total	<u>435,987</u>	<u>325,879</u>

Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.

11. Creditors after one year

	2022	2021
	£	£
Other creditors	3,559,806	3,636,422
Total	<u>3,559,806</u>	<u>3,636,422</u>

The company purchased intellectual property in 2017 for \$5m. The consideration was principally a revenue share with a minimal pre revenue instalment. The long term creditor is the balance due after historic payments have been deducted and presentation of the next annual instalment in short term creditors.

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.